Global SHR0302 Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global SHR0302 market size was valued at US$ 278 million in 2025 and is forecast to a readjusted size of US$ 1234 million by 2032 with a CAGR of 16.9% during review period.
SHR0302 (generic name: Ivarmacitinib) is a highly selective oral JAK1 inhibitor independently developed by Hengrui Medicine. By selectively inhibiting Janus kinase 1 (JAK1), it regulates the signaling pathways of key inflammatory cytokines such as IL‑4, IL‑13, IL‑23, and IFN‑γ, thereby suppressing abnormal immune activation and inflammatory responses. It is mainly indicated for the treatment of a variety of autoimmune and inflammatory skin diseases as well as rheumatic immune disorders. As a new generation of highly selective JAK inhibitors, it exhibits higher subtype selectivity for JAK1, which helps reduce the risk of adverse reactions associated with non-selective inhibition while ensuring therapeutic efficacy. Its approved or investigational indications include atopic dermatitis, rheumatoid arthritis, psoriasis, alopecia areata, vitiligo, among others. As an important immune-targeted drug independently developed and commercialized in China, it demonstrates significant clinical application value and market potential.In 2025, global SHR0302 (Ivarmacitinib) production reached approximately 1.2–1.5 million bottles.
SHR0302 (Ivarmacitinib), as the first highly selective oral JAK1 inhibitor independently developed in China, is positioned at the core of the rapidly growing market for autoimmune diseases. Thanks to its high selectivity for JAK1, it achieves a favorable balance between efficacy and safety, effectively mitigating the risk of adverse reactions associated with non-selective JAK inhibitors. The drug has been approved for multiple indications including ankylosing spondylitis, rheumatoid arthritis, atopic dermatitis and alopecia areata, covering a large patient population.
On the market side, the global market for JAK inhibitors continues to expand, with the domestic market growing notably and long dominated by imported original research drugs. Relying on its advantages as a domestic innovative drug, cost-effective pricing strategy and prospects for medical insurance access, SHR0302 is expected to rapidly achieve import substitution. Meanwhile, the expansion of its indications and the research and development of topical formulations will further unlock its market potential.
In terms of competitive landscape, there are few similar products in China. Hengrui Medicine occupies a leading position in the domestic JAK1 inhibitor sector by virtue of its complete commercialization system and clinical resources. In the future, with the continuous approval of new indications, volume growth under medical insurance coverage and advancement of internationalization, SHR0302 is expected to become a benchmark product in the field of autoimmune diseases in China with sustainable long-term growth potential.
This report is a detailed and comprehensive analysis for global SHR0302 market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global SHR0302 market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global SHR0302 market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global SHR0302 market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global SHR0302 market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for SHR0302
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global SHR0302 market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Jiangsu Hengrui Pharmaceuticals, Arcutis Biotherapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
SHR0302 market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
4mg / tablet
8mg / tablet
Market segment by Dosage Form
Oral Tablet
Topical Ointment
Gel Dosage Form
Market segment by Route of Administration
Oral Administration
Topical Administration
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Application
Inflammatory Skin Diseases Such As Atopic Dermatitis, Psoriasis, Vitiligo And Alopecia Areata
Rheumatic Immune Diseases Such As Rheumatoid Arthritis And Ankylosing Spondylitis
Other Autoimmune And Inflammatory Diseases Mediated By The JAK Pathway
Others
Major players covered
Jiangsu Hengrui Pharmaceuticals
Arcutis Biotherapeutics
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe SHR0302 product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of SHR0302, with price, sales quantity, revenue, and global market share of SHR0302 from 2021 to 2026.
Chapter 3, the SHR0302 competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the SHR0302 breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and SHR0302 market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of SHR0302.
Chapter 14 and 15, to describe SHR0302 sales channel, distributors, customers, research findings and conclusion.